Answers are grounded in this paper and cite their sources.
Targeted α-therapy with ²²⁵Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.
No takes yet. Share an insight, caveat, or question.
Kratochwil et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: